Indicative listing context
Iambic Therapeutics Stock Price (Pre-IPO)
Start Iambic Therapeutics Allocation from $25 → · Stripe checkout (Card, Apple Pay, Link · no password · terms).
Iambic Therapeutics is privately held and not yet trading on a public stock exchange. Iambic Therapeutics' October 8, 2026 Amendment No. 1 to Form S-1 proposes 9,375,000 shares at $15 to $17 per share for listing on the Nasdaq Global Select Market under ticker IAM, following its September 21, 2026 S-1. On Segmara, you can start a Iambic Therapeutics pre-IPO allocation request from $25 ($1.00 Priority Hold available) in USD portfolio credits via Stripe (Card, Apple Pay, Link) without creating a password first, or follow Iambic Therapeutics updates free by email.
Just researching? Get free Iambic Therapeutics mark alerts by email
Indicative private-market reference marks. Direct share allocations and portfolio orders are managed through your Segmara account.
Private-share data lens
Public round-by-round marks are incomplete for this company. Segmara shows the listing mark and keeps the seed-to-IPO analysis focused on verifiable funding, tender, or secondary signals.
| Stage | Date | Valuation / price signal | Why it matters |
|---|---|---|---|
| Seed / early | Private | Not reliably public | Do not invent a seed price when the source set is thin. |
| Growth rounds | Private | Company and market sources vary | Use public sources and official company releases. |
| Segmara listing | Current | No indicative price yet | Indicative reference only, not a quote or an offer. |
| IPO status | Current | No public ticker shown here | Watch official company releases and the free Segmara IPO calendar. |
Seed-to-IPO path
Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.
Pre-IPO Allocation
Request Iambic Therapeutics shares directly.
Start from $25 ($1.00 Priority Hold, no password) via Stripe (Card, Apple Pay, Link) to fund USD portfolio credits toward Iambic Therapeutics shares.
Full shares under $20: Aalo ($1.00) · ID.me ($1.40) · Chainalysis ($6.20) · Precision ($8.18) · Scale AI ($8.78) · Huntress ($19.03)
1Indicative mark: No indicative price yet
2Start from $25 ($1 Hold) via Stripe checkout
3Complete your Iambic Therapeutics share order & track in portfolio
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
| Metric | Value | Context |
|---|---|---|
| Canonical route | /iambic-therapeutics-stock-price | Stable URL path for AI and search extraction. |
| Article title | Iambic Therapeutics Stock Price (Pre-IPO) | Main page topic. |
| Attached public sources | 3 | Number of citation links rendered at the bottom of the article. |
| Segmara listed companies | 148 | Live private-company listings in the public catalogue. |
| Priced listings | 37 | Catalogue listings with visible indicative or direct marks. |
| Listings without an indicative price | 111 | Catalogue listings where a public price is intentionally not invented. |
| Company | Iambic Therapeutics | Named company covered by this page. |
| Symbol label | IAMB | Segmara display symbol; not a public stock ticker unless separately stated. |
| Sector | AI Drug Discovery | Catalogue sector used for comparison and internal linking. |
| Listing structure | Request | How the listing is categorized on Segmara. |
| Segmara mark | No indicative price yet | Visible listing mark, or no indicative price yet. |
| Sector peer count | 2 | Number of live Segmara listings in AI Drug Discovery. |
| Structure peer count | 111 | Number of live Segmara listings categorized as Request. |
Data fingerprint chart
| Stage | Timing | Price / valuation signal | Interpretation |
|---|---|---|---|
| Formation | Private | Early ownership | The first value creation happens before ordinary public-market access. |
| Growth rounds | Private | Institutional repricing | Later rounds and tenders create the price history buyers study. |
| Segmara listing | Current | No indicative price yet | Indicative reference only, not a quote or an offer. |
| Exit path | Future | IPO, tender, acquisition, or continued private status | Liquidity timing remains company-specific. |
| Chart metric | Score | Interpretation |
|---|
Analytical lens
Search intent
Searches like 'Iambic Therapeutics Stock Price (Pre-IPO)' are research questions: what a filing or a company statement confirms, what has only been reported, and what is still unknown.
What counts as a listing step
For an IPO, the primary record is a registration statement filed with the securities regulator of the listing market, such as an S-1 or F-1 on SEC EDGAR for a US listing. Funding rounds, valuations and secondary-market prices are context, not listing steps.
Segmara role
Segmara provides pre-IPO share allocations, Stripe-funded USD portfolio credits from $25 ($1.00 Priority Hold), and dated indicative reference marks across 140+ private companies on Segmara. Nothing on this page is investment advice.
How pre-IPO share access works
Standard Segmara allocation path
1. SearchStart with the company or pre-IPO question
2. ListingReview indicative mark and structure context
3. CheckoutFund from $25 ($1 Priority Hold) via Stripe, no password
4. AllocationRequest pre-IPO shares and track settlement in your portfolio
What happens in your portfolio
Key takeaways
- Iambic Therapeutics is not yet trading on a public retail stock brokerage; Iambic Therapeutics has filed an amended Form S-1 proposing $15 to $17 per share under Nasdaq ticker IAM, without a final IPO pricing or trading date announced.
- Iambic Therapeutics' October 8, 2026 Amendment No. 1 to Form S-1 proposes 9,375,000 shares at $15 to $17 per share for listing on the Nasdaq Global Select Market under ticker IAM, following its September 21, 2026 S-1.
- Fund USD portfolio credits from $25 ($1.00 Priority Hold on Stripe, no password) toward a Iambic Therapeutics allocation request alongside Aspen Neuroscience, Isomorphic Labs, City Therapeutics, and Precision Neuroscience ($8.18/sh).
Risk notes
- Private-company shares and SPV interests are illiquid, transfer-restricted, and subject to issuer approval or closing conditions.
- Preliminary S-1 price ranges and reported private valuations are reference points, not live public exchange quotes.
- Allocation availability depends on counterparty supply, investor eligibility, and Segmara portfolio review.
Public source links
PRE-IPO ALLOCATION
Request Iambic Therapeutics pre-IPO shares
Start from $25 in USD portfolio credits via Stripe (no password required) and request a pre-IPO share allocation in Iambic Therapeutics.
Related reviews
Questions
How do I request pre-IPO shares on Segmara?
Start from $25 ($1.00 Priority Hold, no password) via Stripe checkout or select any of 140+ live private-company listings on Segmara to submit a share allocation request.
How are indicative marks and allocations handled?
Displayed marks are dated indicative references from recent private rounds and secondary activity. Final allocation terms, eligibility, and transfer milestones are tracked in your Segmara portfolio.
Is Segmara affiliated with the named company or platform?
No. Segmara is not affiliated with Iambic Therapeutics or any named issuer, affiliate, investor, underwriter, or platform referenced on this page.
Is Iambic Therapeutics trading publicly right now?
No. Iambic Therapeutics has filed an amended Form S-1 proposing $15 to $17 per share under Nasdaq ticker IAM, without a final IPO pricing or trading date announced.
Can I start a Iambic Therapeutics pre-IPO allocation on Segmara?
Yes. Fund USD portfolio credits starting from $25 ($1.00 Priority Hold, no password required) via Stripe checkout on Segmara, then submit your Iambic Therapeutics allocation request for review.
What peers can I compare alongside Iambic Therapeutics?
Compare Iambic Therapeutics alongside Aspen Neuroscience, Isomorphic Labs, City Therapeutics, and Precision Neuroscience ($8.18/sh) across 148 pre-IPO listings on Segmara, including 6 full-share listings priced from $1.00 to $19.03.
Pre-IPO Allocation
Request Iambic Therapeutics shares on Segmara.
Start from $25 ($1 Priority Hold available) via Stripe with no password required, fund USD portfolio credits, and request a pre-IPO allocation in Iambic Therapeutics.
Full shares under $20: Aalo ($1.00) · ID.me ($1.40) · Chainalysis ($6.20) · Precision ($8.18) · Scale AI ($8.78) · Huntress ($19.03)